Fluctuation trend of inflammatory indexes related to gestational diabetes mellitus from second trimester to third trimester of pregnancy.
Humans
Female
Pregnancy
Diabetes, Gestational
/ blood
Pregnancy Trimester, Second
/ blood
Pregnancy Trimester, Third
/ blood
Adult
NLR Family, Pyrin Domain-Containing 3 Protein
/ blood
Interleukin 1 Receptor Antagonist Protein
/ blood
Biomarkers
/ blood
Inflammation
/ blood
Case-Control Studies
TATA-Binding Protein Associated Factors
/ blood
Body Mass Index
Birth Weight
Gestational diabetes mellitus
IL-1Ra
NLRP3
TBP-2
Journal
BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799
Informations de publication
Date de publication:
12 Oct 2024
12 Oct 2024
Historique:
received:
29
03
2024
accepted:
20
09
2024
medline:
13
10
2024
pubmed:
13
10
2024
entrez:
12
10
2024
Statut:
epublish
Résumé
This study aims to assess the prognostic and diagnostic value of inflammatory indexes related to gestational diabetes mellitus (GDM) from the second trimester to the third trimester of pregnancy. In this study, we randomly selected 65 pregnant women diagnosed with GDM at our hospital from December 2022 to June 2023 to form the GDM group (n = 65). Additionally, 65 pregnant women at the same gestational weeks without GDM were selected as the Normal group (n = 65). We collected gestational information and serum samples at 24 and 36 weeks of gestation from the participants. The levels of NLRP3, IL-1Ra, and TBP-2 were determined using enzyme-linked immunosorbent assay (ELISA) to explore their changes during pregnancy. Further, this study analyzed the changes in the levels of NLRP3, IL-1Ra, and TBP-2 at 24 and 36 weeks of gestation in GDM patients and their correlation with gestational diabetes mellitus. The study showed that pre-pregnancy body mass index (BMI), neonatal weight, gestational hypertension, and macrosomia are significantly associated with the occurrence of GDM (P < 0.05). Statistical analysis comparing the normal and GDM groups found no significant changes in the levels of NLRP3, IL-1Ra, and TBP-2 with the progression of gestation in the normal group. In contrast, in the GDM group, the levels of IL-1Ra in serum samples at 24 and 36 weeks were significantly increased (P < 0.05) while the levels of NLRP3 and TBP-2 were significantly reduced (P < 0.05). At 36 weeks, there was a positive correlation between the levels of NLRP3, IL-1Ra, and TBP-2. Compared to the normal group, the overall levels of NLRP3, IL-1Ra, and TBP-2 in the GDM group were lower (P < 0.05) and the weight of the newborns was significantly correlated with these three indicators (P < 0.05), specifically newborn weight increased with the levels of NLRP3 and TBP-2 but decreased with the increase of IL-1Ra (P < 0.05). Multifactorial logistic regression analysis further revealed that NLRP3 is an independent factor influencing GDM (P < 0.05). ROC curve analysis of the NLRP3 level at 24 weeks of gestation found that NLRP3 has a good value in predicting GDM (AUC = 0.720, 95%CI 0.630-0.809, P < 0.001) and the combined prediction of NLRP3, IL-1Ra, and TBP-2 also showed a good predictive value for GDM. The changes in NLRP3, IL-1Ra, and TBP-2 persisted throughout the 24 to 36 weeks of gestation, playing an important role in predicting the occurrence of GDM and the weight of the newborn.
Identifiants
pubmed: 39395929
doi: 10.1186/s12884-024-06846-9
pii: 10.1186/s12884-024-06846-9
doi:
Substances chimiques
NLR Family, Pyrin Domain-Containing 3 Protein
0
Interleukin 1 Receptor Antagonist Protein
0
NLRP3 protein, human
0
Biomarkers
0
TATA-Binding Protein Associated Factors
0
IL1RN protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
665Informations de copyright
© 2024. The Author(s).
Références
Gao C, Sun X, Lu L, Liu F, Yuan J. Prevalence of gestational diabetes mellitus in mainland China: a systematic review and meta-analysis. J Diabetes Investig. 2019;10(1):154–62. https://doi.org/10.1111/jdi.12854 . Epub 2018 May 27. PMID: 29683557; PMCID: PMC6319492.
doi: 10.1111/jdi.12854
pubmed: 29683557
Ye W, Luo C, Huang J, Li C, Liu Z, Liu F. Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis. BMJ. 2022;377:e067946. https://doi.org/10.1136/bmj-2021-067946 . PMID: 35613728; PMC9ID: PMC131781.
doi: 10.1136/bmj-2021-067946
pubmed: 35613728
pmcid: 9131781
Yingying H, Chu Qian. Correlation between indicators related to islet function during pregnancy and postpartum glucose tolerance in pregnant women with GDM [J]. Progress Mod Obstet Gynecol. 2023;32(07):535–7.
Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes Mellitus. Int J Mol Sci. 2018;19(11):3342. https://doi.org/10.3390/ijms19113342 . PMID: 30373146; PMCID: PMC6274679.
doi: 10.3390/ijms19113342
pubmed: 30373146
pmcid: 6274679
Juan J, Yang H, Prevalence. Prevention, and Lifestyle intervention of gestational diabetes Mellitus in China. Int J Environ Res Public Health. 2020;17(24):9517. https://doi.org/10.3390/ijerph17249517 . PMID: 33353136; PMCID: PMC7766930.
doi: 10.3390/ijerph17249517
pubmed: 33353136
pmcid: 7766930
Chávez-García L, Valle-Leal JG, Jiménez-Mapula C, Quintero-Medrano SM, López-Villegas MN. Adherencia terapéutica y control glucémico en pacientes con diabetes gestacional bajo dos esquemas de tratamiento [Gestational diabetes, adherence to treatment, and metabolic control]. Rev Med Chil. 2019;147(5):574–8. https://doi.org/10.4067/S0034-98872019000500574 . Spanish. PMID: 31859889.
doi: 10.4067/S0034-98872019000500574
pubmed: 31859889
Phoswa WN, Khaliq OP. The role of oxidative stress in Hypertensive disorders of pregnancy (Preeclampsia, gestational hypertension) and metabolic disorder of pregnancy (gestational diabetes Mellitus). Oxid Med Cell Longev. 2021;2021:5581570. https://doi.org/10.1155/2021/5581570 . PMID: 34194606; PMCID: PMC8184326.
doi: 10.1155/2021/5581570
pubmed: 34194606
pmcid: 8184326
Huang TT, Sun WJ, Liu HY, Ma HL, Cui BX. p66Shc-mediated oxidative stress is involved in gestational diabetes mellitus. World J Diabetes. 2021;12(11):1894–907. https://doi.org/10.4239/wjd.v12.i11.1894 . PMID: 34888014; PMCID: PMC8613666.
doi: 10.4239/wjd.v12.i11.1894
pubmed: 34888014
pmcid: 8613666
Mirabelli M, Chiefari E, Tocci V, Greco E, Foti D, Brunetti A. Gestational diabetes: implications for fetal growth, intervention timing, and treatment options. Curr Opin Pharmacol. 2021;60:1–10. https://doi.org/10.1016/j.coph.2021.06.003 . Epub 2021 Jul 14. PMID: 34280703.
doi: 10.1016/j.coph.2021.06.003
pubmed: 34280703
Fang X, Miao R, Wei J, Wu H, Tian J. Advances in multi-omics study of biomarkers of glycolipid metabolism disorder. Comput Struct Biotechnol J. 2022;20:5935–51. https://doi.org/10.1016/j.csbj.2022.10.030 . PMID: 36382190; PMCID: PMC9646750.
doi: 10.1016/j.csbj.2022.10.030
pubmed: 36382190
pmcid: 9646750
Mahmoudi Azar L, Karaman E, Beyaz B, Göktan I, Eyüpoğlu AE, Kizilel S, Erman B, Gül A, Uysal S. Expression and characterization of recombinant IL-1Ra in aspergillus oryzae as a system. BMC Biotechnol. 2023;23(1):15. https://doi.org/10.1186/s12896-023-00785-7 . PMID: 37340430; PMCID: PMC10283290.
doi: 10.1186/s12896-023-00785-7
pubmed: 37340430
pmcid: 10283290
Zhan X, Li Q, Xu G, Xiao X, Bai Z. The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors. Front Immunol. 2023;13:1109938. https://doi.org/10.3389/fimmu.2022.1109938 . PMID: 36741414; PMCID: PMC9889537.
doi: 10.3389/fimmu.2022.1109938
pubmed: 36741414
pmcid: 9889537
Yu Q, Liu M, Dai W, Xiong Y, Mu X, Xia M, Li Y, Ma S, Su Y, Wu J, Liu C, Xie Y, Zhao T, Lu A, Weng N, Zheng F, Sun P. The NLRP3 inflammasome is involved in resident intruder paradigm-induced aggressive behaviors in mice. Front Pharmacol. 2023;14:974905. doi:.3389/fphar.2023.974905. PMID: 36778007; PMCID: PMC9912938.
Yoshihara E. TXNIP/TBP-2: a Master Regulator for glucose homeostasis. Antioxid (Basel). 2020;9(8):765. https://doi.org/10.3390/antiox9080765 . PMID: 32824669; PMCID: PMC7464905.
doi: 10.3390/antiox9080765
Zhang X, Deng Dongrui. Progress in pyroptosis and inflammasomes in pregnancy-related diseases [J]. Progress Mod Obstet Gynecol. 2023;31(10):795–7.
Potere N, Del Buono MG, Caricchio R, Cremer PC, Vecchié A, Porreca E, Dalla Gasperina D, Dentali F, Abbate A, Bonaventura A. Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications. EBioMedicine. 2022;85:104299. https://doi.org/10.1016/j.ebiom.2022.104299 . Epub 2022 Oct 6. PMID: 36209522; PMCID: PMC9536001.
doi: 10.1016/j.ebiom.2022.104299
pubmed: 36209522
pmcid: 9536001
Linlin T, Wang Yaping. Plasma IL-1 Ra level and its association with postpartum type 2 diabetes among women with gestational diabetes [J]. Mod Med. 2023;50(07):864–70.